Pfizer Inc. (NYSE:PFE) shares, rose in value on Wednesday, 05/24/23, with the stock price down by -2.55% to the previous day’s close as strong demand from buyers drove the stock to $38.63.
Actively observing the price movement in the last trading, the stock closed the session at $39.64, falling within a range of $38.60 and $40.14. The PE ratio was 7.61 over 12-month period. Referring to stock’s 52-week performance, its high was $54.93, and the low was $36.17. On the whole, PFE has fluctuated by -1.78% over the past month.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
With the market capitalization of Pfizer Inc. currently standing at about $216.36 billion, investors are eagerly awaiting this quarter’s results, scheduled for Jul 26, 2023 – Jul 31, 2023. The company’s Forward Dividend Ratio is 1.64, with its dividend yield at 4.25%. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.61, which is expected to increase to $1.09 for fiscal year $3.34 and then to about $3.54 by fiscal year 2024. Data indicates that the EPS growth is expected to be -49.20% in 2024, while the next year’s EPS growth is forecast to be 6.00%.
Analysts have estimated the company’s revenue for the quarter at $13.86 billion, with a low estimate of $11.98 billion and a high estimate of $15.99 billion. According to the average forecast, sales growth in current quarter could jump down -50.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $67.57 billion, representing a decrease of -32.70% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that PFE’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
25 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 14 analyst(s), 9 recommend it as a Buy and 2 called the PFE stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of PFE currently trading nearly 1.31% and -2.50% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.19, while the 7-day volatility ratio is showing 4.03% which for the 30-day chart, stands at 2.10%. Furthermore, Pfizer Inc. (PFE)’s beta value is 0.63, and its average true range (ATR) is 0.89. The company’s stock has been forecasted to trade at an average price of $46.68 over the course of the next 52 weeks, with a low of $38.00 and a high of $75.00. Based on these price targets, the low is 1.63% off current price, whereas the price has to move -94.15% to reach the yearly target high. Additionally, analysts’ median price of $44.00 is likely to be welcomed by investors because it represents a decrease of -13.9% from the current levels.
A comparison of Pfizer Inc. (PFE) with its peers suggests the former has fared considerably weaker in the market. PFE showed an intraday change of -2.55% in last session, and over the past year, it shrunk by -26.95%%. In comparison, Johnson & Johnson (JNJ) has moved lower at -0.10% on the day and was down -12.70% over the past 12 months. On the other hand, the price of Eli Lilly and Company (LLY) has risen 0.60% on the day. The stock, however, is off 40.70% from where it was a year ago. Additionally, there is a loss of -1.61% for Abbott Laboratories (ABT) in last trading while the stock has seen an overall depriciation of -9.55%% over the past year. The PE ratio stands at 7.61 for Pfizer Inc., compared to 32.77 for Johnson & Johnson, and 67.59 for Eli Lilly and Company. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.73%. Meanwhile, the Dow Jones Industrial Slipped by -0.77%.
Data on historical trading for Pfizer Inc. (NYSE:PFE) indicates that the trading volumes over the past 10 days have averaged 37.16 million and over the past 3 months, they’ve averaged 23.93 million. According to company’s latest data on outstanding shares, there are 5.63 billion shares outstanding.
Nearly 0.04% of Pfizer Inc.’s shares belong to company insiders and institutional investors own 70.50% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 43.87 million shares as on Apr 27, 2023, resulting in a short ratio of 2.23. According to the data, the short interest in Pfizer Inc. (PFE) stood at 0.78% of shares outstanding as of Apr 27, 2023; the number of short shares registered in Mar 30, 2023 reached 49.07 million. The stock has fallen by -24.61% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PFE stock heading into the next quarter.